Studies on DEVELOPMENT OF ImMUNOTHERAPY FOR ORAL CANCERS BY INTERLEUKIN 2

口腔癌患者的淋巴细胞在体外与白细胞介素2（IL 2）共同孵育后可产生抗肿瘤杀伤活性。用单克隆抗体检测了外周血淋巴细胞（PBL）、淋巴结细胞（LNC）和肿瘤浸润淋巴细胞（TIL）的活化杀伤细胞来源，并分析了这些细胞的细胞表面标志。在此基础上，进行了IL-2免疫治疗口腔癌的早期Ⅱ期临床研究，采用体外培养的方法，观察IL-2对口腔癌患者外周血淋巴细胞（PBL）自然杀伤（NK）活性的增强和淋巴因子激活的杀伤（LAK）活性的产生。NK和LAK活性的升高无显著性差异。通过IL-2在健康供体和口腔癌患者和/或肿瘤阶段之间的作用。经IL-2激活后，口腔癌患者的淋巴细胞也表现出较高的NK活性，但LAK活性明显低于PBL，产生NK和LAK活性的前体淋巴细胞表面标志物均为CD 3-CD 16或CD 3-Leu 7，但不能排除淋巴细胞表达CD 3的可能性。7名口腔癌患者通过病灶内注射IL-2治疗，9名类似患者通过静脉内途径治疗。在一些病灶内免疫治疗的病例中观察到了明显的肿瘤缩小效果。并检测了IL-2治疗后患者NK和LAK活性。

The lymphocytes from oral cancer patients have been to be able to generate anti-tumor killer activities by incubating with interleukin 2 (IL2) in vitro. Peripheral blood lymphocytes (PBL), lymphonodal cells (LNC) and tumoe infiltrating lymphocytes (TIL) have been examined for the sourse of the activated killer cells, and cell surface markers of those cells have been analysed by monoclonal antibodies. Then, the early phase II clinical study of immounotherapy with IL-2 on oral cancer patients has been performed.The augumentation of natural killer (NK) activity and the generation of lymphokine activated killer (LAK) activity were observed by in vitro incubation of PBL with IL-2 for 5 days. No significant difference was found in the augumentation of NK and LAK activities. by IL-2 between healthy donors and oral cancer patients and / or tumor stages. LNC from oral cancer patients also showed high NK activity after the activation by IL-2, however, LAK activity of LNC were significantly lower than that of PBL.Cell surface markers of precourser lymphocytes which generate NK and LAK activites expressed either CD3 CD16 or CD3 Leu7, however, possibility of T lymphocytes expreesing CD3 could not be rouled out in case of LNC.As for the early phase II clinical trial, seven oral cancer patients have been treated by intralesional injection of IL-2, and nine similar patients have been treated by intra venous rout. Obvious tumor reduction effect has been observed in some cases of intralesional immunotherapy. NK and LAK activeties of IL-2 treated patients have been also examined.